NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
University Hospital, Bordeaux
Case Comprehensive Cancer Center
French Innovative Leukemia Organisation